SCHEMBL3968650

SCHEMBL3968650

[CH2]Oc1c(C)c(C)nc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.52
POLB P06746 1/20 0.50
PDE10A Q9Y233 1/20 0.50
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HPGD P15428 1/20 0.47
NUDT1 P36639 1/20 0.47
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GLA P06280 1/20 0.44
CASP3 P42574 1/20 0.44
HTT P42858 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999688 0.83 POLB (0.68) GPR3POLBPDE10AALDH1A1CYP1A2
SCHEMBL7259506 0.81 GPR3 (0.47) GPR3POLBPDE10AALDH1A1CYP1A2
SCHEMBL5502106 0.76 GPR3 (0.46) GPR3POLBPDE10AALDH1A1CYP1A2
SCHEMBL1278314 0.76 PDE10A (0.57) GPR3POLBPDE10AALDH1A1CYP1A2
SCHEMBL231530 0.76 GPR3 (0.64) GPR3POLBPDE10AALDH1A1CYP1A2
SCHEMBL6788479 0.75 GPR3 (0.57) GPR3POLBPDE10AALDH1A1CYP1A2
SCHEMBL3966414 0.75 GPR3 (0.57) GPR3POLBPDE10AALDH1A1CYP1A2
Ammonia Solution, Strong SCHEMBL28822932 0.74 GPR3 (0.61) GPR3POLBPDE10AALDH1A1CYP1A2
Hydrochloric Acid SCHEMBL27521191 0.74 GPR3 (0.61) GPR3POLBPDE10AALDH1A1CYP1A2
SCHEMBL30025532 0.72 ALDH1A1 (0.64) GPR3POLBPDE10AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
US-6936620-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL MYERS SQUIBB COMPANY (US) 2005-08-30 US disclosed
WO-2003053940-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-$G(A) CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 GPR3 3290/4885POLB 1914/4885PDE10A 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.